PHARMETAL
ActiveFinancials · financial year 2025, micro format
2025 annual accounts filed 30 days after the deadline Filed on 30 August 2026, deadline 31 July 2026 (7 months after the close on 31 December 2025, Companies Code art. 3:10). Source: NBB, 2026-00454892.
Annual accounts 2025 filed on 30-08-2026 at the NBB all 47 filings
Every figure per financial year
The operating result for 2025 is a loss of €2,447, smaller than the loss of €3,663 in 2024.
Turnover and EBIT margin are not published. The micro format does not require them.
| Line | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|---|
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | - | €494 | €395 | €316 | €253 | €247 | €247 | €247 | = |
| Other operating charges640/8 | - | - | - | €368 | €368 | €384 | €440 | €400 | ▼ 9.2% |
| Gross operating margin9900 | €6,608 | -€5,313 | -€3,211 | -€2,115 | -€1,966 | -€4,771 | -€2,976 | -€1,800 | ▲ 39.5% |
| Operating profit (loss)9901 | €6,240 | -€6,174 | -€3,974 | -€2,799 | -€2,586 | -€5,402 | -€3,663 | -€2,447 | ▲ 33.2% |
| Financial income75/76B | - | - | - | €12,921 | €11,137 | €12,957 | €27,326 | €4,914 | ▼ 82.0% |
| Recurring financial income75 | €8,340 | €3,750 | - | €12,921 | €11,137 | €12,957 | €27,326 | €4,914 | ▼ 82.0% |
| Financial charges65/66B | - | - | - | €216 | €237 | €8,500 | €228 | €20,266 | ▲ 89× |
| Recurring financial charges65 | €132 | €185 | €15,591 | €216 | €237 | €8,500 | €228 | €20,266 | ▲ 89× |
| Profit (loss) for the period before taxes9903 | €14,448 | -€2,609 | -€19,565 | €9,906 | €8,313 | -€945 | €23,434 | -€17,799 | - |
| Income taxes67/77 | €4,160 | €1,286 | €61 | €59 | €252 | €491 | €7,083 | €666 | ▼ 90.6% |
| Profit (loss) for the period9904 | €10,288 | -€3,894 | -€19,626 | €9,847 | €8,061 | -€1,436 | €16,351 | -€18,466 | - |
| Profit (loss) for the period to be appropriated9905 | €10,288 | -€3,894 | -€19,626 | €9,847 | €8,061 | -€1,436 | €16,351 | -€18,466 | - |
| Line | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||
| Total assets20/58 | €414,657 | €405,693 | €379,224 | €389,066 | €397,522 | €375,746 | €394,375 | €375,906 | ▼ 4.7% |
| Fixed assets21/28 | €196 | €2,173 | €1,778 | €1,461 | €1,208 | €961 | €714 | €467 | ▼ 34.6% |
| Tangible fixed assets22/27 | - | €1,977 | €1,581 | €1,265 | €1,012 | €765 | €518 | €271 | ▼ 47.7% |
| Plant, machinery and equipment23 | - | - | - | €1,265 | €1,012 | €765 | €518 | €271 | ▼ 47.7% |
| Furniture and vehicles24 | - | - | - | - | - | - | €0 | €0 | - |
| Financial fixed assets28 | €196 | €196 | €196 | €196 | €196 | €196 | €196 | €196 | = |
| Current assets29/58 | €414,461 | €403,520 | €377,447 | €387,605 | €396,314 | €374,784 | €393,661 | €375,439 | ▼ 4.6% |
| Amounts receivable within one year40/41 | €3,630 | €168 | €168 | €168 | €168 | €8,523 | €3,377 | €189 | ▼ 94.4% |
| Other amounts receivable41 | - | - | - | €168 | €168 | €8,523 | €3,377 | €189 | ▼ 94.4% |
| Current investments50/53 | - | - | - | - | - | €349,081 | €373,865 | €370,820 | ▼ 0.8% |
| Cash at bank and in hand54/58 | €410,113 | €402,615 | €376,950 | €384,828 | €390,926 | €9,975 | €11,864 | €3,578 | ▼ 69.8% |
| Deferred charges and accrued income490/1 | - | - | - | €2,609 | €5,220 | €7,206 | €4,556 | €851 | ▼ 81.3% |
| Equity and liabilities | |||||||||
| Total equity and liabilities10/49 | €414,657 | €405,693 | €379,224 | €389,066 | €397,522 | €375,746 | €394,375 | €375,906 | ▼ 4.7% |
| Equity10/15 | €401,452 | €397,558 | €377,931 | €387,779 | €395,840 | €373,944 | €390,295 | €371,829 | ▼ 4.7% |
| Contributions10/11 | €18,600 | €18,600 | €18,600 | €18,600 | €18,600 | - | - | - | - |
| Capital10 | - | - | - | €18,600 | €18,600 | - | - | - | - |
| Issued capital100 | - | - | - | €18,600 | €18,600 | - | - | - | - |
| Reserves13 | €195,461 | €195,461 | €195,461 | €195,461 | €195,461 | €193,601 | €193,601 | €193,601 | = |
| Non-distributable reserves130/1 | - | - | - | €1,860 | €1,860 | - | - | - | - |
| Legal reserve130 | - | - | - | €1,860 | €1,860 | - | - | - | - |
| Distributable reserves133 | - | - | - | €193,601 | €193,601 | €193,601 | €193,601 | €193,601 | = |
| Profit (loss) carried forward14 | €187,391 | €183,497 | €163,870 | €173,718 | €181,779 | €180,343 | €196,694 | €178,228 | ▼ 9.4% |
| Amounts payable17/49 | €13,205 | €8,136 | €1,293 | €1,287 | €1,682 | €1,802 | €4,081 | €4,077 | ▼ 0.1% |
| Amounts payable within one year42/48 | €13,205 | €8,136 | €1,293 | €1,287 | €1,682 | €1,802 | €4,081 | €4,077 | ▼ 0.1% |
| Trade debts44 | €425 | €516 | €1,156 | €1,004 | €1,361 | €1,564 | €170 | €1,905 | ▲ 11× |
| Suppliers440/4 | - | - | - | €1,004 | €1,361 | €1,564 | €170 | €1,905 | ▲ 11× |
| Taxes, remuneration and social security45 | - | - | - | €59 | €252 | €169 | €2,980 | €2,172 | ▼ 27.1% |
| Taxes450/3 | - | - | - | €59 | €252 | €169 | €2,980 | €2,172 | ▼ 27.1% |
| Other amounts payable47/48 | - | - | - | €224 | €69 | €69 | €931 | - | - |
| Line | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|---|
| Profit (loss) for the period9904 | €10,288 | -€3,894 | -€19,626 | €9,847 | €8,061 | -€1,436 | €16,351 | -€18,466 | - |
| + Depreciation and write-downs630 | - | €494 | €395 | €316 | €253 | €247 | €247 | €247 | = |
| Operating cash flow (approximation) | €10,288 | -€3,400 | -€19,231 | €10,164 | €8,314 | -€1,189 | €16,598 | -€18,219 | - |
| Investment in fixed assets (approximation) | - | -€2,471 | €0 | €0 | €0 | €0 | €0 | €0 | - |
| Change in cash | - | -€7,498 | -€25,665 | €7,878 | €6,098 | -€380,951 | €1,889 | -€8,285 | - |
A Belgian filing has no cash-flow statement. These rows are therefore an approximation, derived from the income statement and the balance-sheet moves.
Historical observation
In July 2024, 12,322 companies had the same profile as PHARMETAL has now. Two years later, 90.3% were still going and 0.7% had gone bankrupt.
- Micro
- 20 years or older
- solvency 30% or more
- a small loss
Another 0.5% stopped without a precise date, possibly only after those two years.
That fits the bankruptcy probability of PHARMETAL itself: 0.1% within 12 months.
Test of the method
The method was tested on the 497,446 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 12,322 companies, not a prediction for PHARMETAL. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Latest 10 of 47 filings with the National Bank
| Financial year | Type | Filed | Reference | Document |
|---|---|---|---|---|
| 31-12-2025 | micro format | 30-08-2026 | 2026-00454892 | |
| 31-12-2024 | micro format | 28-08-2025 | 2025-00418494 | |
| 31-12-2023 | micro format | 30-08-2024 | 2024-00438325 | |
| 31-12-2022 | micro format | 31-08-2023 | 2023-00416753 | |
| 31-12-2021 | micro format | 30-08-2022 | 2022-20410466 | |
| 31-12-2020 | micro format | 31-08-2021 | 2021-62300374 | |
| 31-12-2019 | micro format | 30-10-2020 | 2020-68800487 | |
| 31-12-2018 | micro format | 30-08-2019 | 2019-59300273 | |
| 31-12-2017 | micro format | 31-08-2018 | 2018-58700233 | |
| 31-12-2016 | micro format | 31-08-2017 | 2017-56200334 |